These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25900265)

  • 1. Differential Lipid Response to Statins Is Associated With Variants in the BUD13-APOA5 Gene Region.
    OʼBrien SE; Schrodi SJ; Ye Z; Brilliant MH; Virani SS; Brautbar A
    J Cardiovasc Pharmacol; 2015 Aug; 66(2):183-8. PubMed ID: 25900265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of polymorphisms in APOA4-APOA5-ZPR1-BUD13 gene cluster and sleep duration on 5-year lipid changes in middle aged and older Chinese.
    Yang L; Ma L; Guo W; Fang Q; Lai X; Zhang X
    Sleep; 2019 Aug; 42(8):. PubMed ID: 31181149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
    Brautbar A; Covarrubias D; Belmont J; Lara-Garduno F; Virani SS; Jones PH; Leal SM; Ballantyne CM
    Atherosclerosis; 2011 Dec; 219(2):737-42. PubMed ID: 21889769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.
    Lai CQ; Arnett DK; Corella D; Straka RJ; Tsai MY; Peacock JM; Adiconis X; Parnell LD; Hixson JE; Province MA; Ordovas JM
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1417-25. PubMed ID: 17431185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
    Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
    DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of apolipoprotein A5 variants on statin treatment efficacy.
    Hubacek JA; Adamkova V; Prusikova M; Snejdrlova M; Hirschfeldova K; Lanska V; Ceska R; Vrablik M
    Pharmacogenomics; 2009 Jun; 10(6):945-50. PubMed ID: 19530961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triglyceride-raising APOA5 genetic variants are associated with obesity and non-HDL-C in Chinese children and adolescents.
    Zhu WF; Wang CL; Liang L; Shen Z; Fu JF; Liu PN; Lv LQ; Zhu YM
    Lipids Health Dis; 2014 Jun; 13():93. PubMed ID: 24903888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome.
    Li XP; Gong HR; Huang XS; Huang WY; Zhao SP
    Lipids Health Dis; 2013 Sep; 12():133. PubMed ID: 24016248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Polymorphisms in APOA4-APOA5-ZNF259-BUD13 Gene Cluster on Plasma Levels of Triglycerides and Risk of Coronary Heart Disease in a Chinese Han Population.
    Fu Q; Tang X; Chen J; Su L; Zhang M; Wang L; Jing J; Zhou L
    PLoS One; 2015; 10(9):e0138652. PubMed ID: 26397108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma fasting and nonfasting triglycerides and high-density lipoprotein cholesterol in atherosclerotic stroke: different profiles according to low-density lipoprotein cholesterol.
    Kim SJ; Park YG; Kim JH; Han YK; Cho HK; Bang OY
    Atherosclerosis; 2012 Aug; 223(2):463-7. PubMed ID: 22683121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic study of statin therapy and cholesterol reduction.
    Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
    JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association and interaction of APOA5, BUD13, CETP, LIPA and health-related behavior with metabolic syndrome in a Taiwanese population.
    Lin E; Kuo PH; Liu YL; Yang AC; Kao CF; Tsai SJ
    Sci Rep; 2016 Nov; 6():36830. PubMed ID: 27827461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
    Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
    Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.
    Polisecki E; Muallem H; Maeda N; Peter I; Robertson M; McMahon AD; Ford I; Packard C; Shepherd J; Jukema JW; Westendorp RG; de Craen AJ; Buckley BM; Ordovas JM; Schaefer EJ;
    Atherosclerosis; 2008 Sep; 200(1):109-14. PubMed ID: 18261733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between the distribution of plasma HDL subclasses and the polymorphisms of APOA5 in hypertriglyceridemia.
    Long S; Chen Z; Han Y; Christopher DM; Zhang C; Yang Y; Tian Y
    Clin Biochem; 2013 Jun; 46(9):733-9. PubMed ID: 23499587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of apolipoprotein A-V concentration with apolipoprotein A5 gene -1131T>C polymorphism and fasting triglyceride levels.
    Kim JY; Kim OY; Paik JK; Lee SH; Lee JH
    J Clin Lipidol; 2013; 7(2):94-101. PubMed ID: 23415427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy.
    Brautbar A; Barbalic M; Chen F; Belmont J; Virani SS; Scherer S; Hegele RA; Ballantyne CM
    J Lipid Res; 2013 Jul; 54(7):1980-7. PubMed ID: 23633496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.